The Management Team

Ray E. Peck

Chief Executive Officer

With over 25 years’ experience in front line business development, as well as sales management, Ray has worked in over a dozen countries, and on almost every continent. He is multi-lingual, and has worked with Global “Big Pharma” clients, as well as with the entrepreneurs at small virtual companies. He has held positions of increasing responsibility including Director of North American and European – Pharma/Biotech Business Development, Director of Global Strategic Accounts at Azopharma, Executive Director at CoreRx Pharma Services, and most recently as Founder and CEO of CRO Solutions. Ray’s focus has been in drug development services from discovery chemistry, to clinical trial materials, and to niche commercial manufacturing, including both small molecule and large molecule programs. Ray founded CRO Solutions/VxP Biologics in 2010, which has since grown to include contract labs on several continents, and in almost every area of drug development. Ray holds a BS from Michigan State.

Kimberly Keepper

Chief Financial Officer

Ms. Keepper has over 25 years’ experience in management, accounting and finance. She received her BS in Accounting and Finance from Lipscomb University in Nashville, TN, and went on to earn her CPA. Kim spent seven years at KPMG, where she served in multiple roles, including Audit Manager over several large publicly traded companies. Kim spent four years in Japan working on the AAFES Management Team, and continued on for three years in positions of increasing responsibility in the United States. In 2002, Kim joined Renal Care Group, a kidney dialysis company, as Regional Controller. In 2008, Kim became Revenue Controller at Fresenius Medical Care, the largest kidney dialysis company in the United States, and one of the largest in the world. Kim has served as our Chief Financial Officer since 2010.

Ann Newman, PhD.

Senior Scientific Advisor

Dr. Ann Newman is currently a pharmaceutical consultant at Seventh Street Development Group with over 20 years of large pharma and contract research experience. Dr. Newman received her PhD in Chemistry from the University of Connecticut. For ten years, Dr. Newman performed characterization studies on a wide range of pharmaceutical systems at Bristol-Meyers Squibb, covering drug substance and product scale-up from late drug discovery to launch and manufacturing. After that she was Vice President of Materials Science at SSCI, Inc. overseeing characterization of API and drug product samples, crystallization and polymorph screens, salt and cocrystal selections, quantitative assays, amorphous projects, and problem solving for the pharmaceutical industry. As Vice President of Research and Development at Aptuit, she instituted a companywide R&D initiative over six global sites and covering areas such as API, preclinical (toxicology, safety, pharmacokinetics), formulation, solids, analytical, clinical packaging, and regulatory. She holds an adjunct faculty position in Industrial and Physical Pharmacy at Purdue University and is a collaborator on over 40 publications and over 75 technical presentations.

Ann Newman